Probetol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Probetol

Quick Facts

Property Description
Active ingredient Propranolol hydrochloride
Form Tablets, Oral Solution, Extended-Release Capsules
Pharmacological class Non-selective Beta-Adrenergic Receptor-Blocking Agent
General purpose To stabilize cardiovascular and neurogenic activity
Origin Synthetic compound

Probetol is a synthesized pharmaceutical preparation containing Propranolol hydrochloride as its single active ingredient. It is classified as a non-selective beta-adrenergic receptor-blocking agent, or beta blocker, used generally to regulate cardiovascular and nervous system activity.

What Type of Drug is Probetol (Propranolol)?

Probetol is a prescription-only medication that belongs to the therapeutic class of beta blockers, a class clinically recognized for its essential role in long-term cardiovascular management. Propranolol is a highly lipophilic agent with a recognized ability to cross the blood-brain barrier. As a synthetic compound, Probetol functions by acting as a non-selective antagonist, a key feature that distinguishes it from selective beta-blockers by blocking the effects of stimulating hormones on both beta-1 and beta-2 adrenergic receptors.

Composition and Available Forms of Probetol

The active core of Probetol is Propranolol, which is typically present as a racemic mixture of two enantiomers, with the S(-)-enantiomer primarily providing the therapeutic benefit of beta blockade. This agent is available for oral administration in multiple physical forms, including standard film-coated tablets and specialized extended-release capsules designed to provide a sustained level of the drug over a longer duration. Propranolol is available for both oral and intravenous injection routes.

General Purpose and Effect of Probetol

The general purpose of Probetol is to stabilize the body's cardiovascular and neurogenic functions by mitigating the influence of stress hormones. By preventing catecholamines like epinephrine from binding to their receptors, Probetol effectively works to ease the workload of the heart through a reduction in both the heart rate and the force of its contractions. This general action ultimately serves to control and regulate vital circulatory activity and diminish exaggerated physical responses driven by the sympathetic nervous system, such as rapid heart rhythms.

Regulatory References

  1. NIH DailyMed drug label for Propranolol

What side effects are possible with Probetol?

Possible Side Effects and Safety Information

The safety profile for Probetol (Propranolol hydrochloride) is based on classifications from major government regulatory authorities. Adverse reactions are grouped by frequency and the body system affected, providing a structured view of documented risks.

The most common reported adverse reactions often involve the Nervous System and Gastrointestinal System. These include fatigue, sleep disturbances, nightmares, nausea, vomiting, and experiencing cold extremities.

Documented Adverse Reaction Frequencies

Frequency Classification Examples of Adverse Reactions (by SOC)
Common Fatigue, sleep disturbances, cold extremities, diarrhea
Uncommon Dry mouth
Rare Bradycardia, heart failure, bronchospasm, thrombocytopenia
Very Rare Systemic lupus erythematosus (SLE)

Serious Adverse Reactions and Safety Constraints

Official labels document serious adverse reactions, primarily affecting the Cardiovascular System. These include the potential for severe bradycardia (slow heart rate), the worsening of pre-existing heart failure, and the risk of bronchospasm (airway constriction), which is classified as rare.

Safety constraints are noted for specific populations. For instance, caution is required in patients with severe hepatic or renal impairment due to altered drug clearance. Furthermore, Probetol may mask the signs of acute hypoglycemia in diabetic patients. A key safety pattern documented in regulatory texts is the risk of a withdrawal syndrome, including the potential for exacerbated angina or myocardial infarction, if the drug is stopped abruptly.

Overdose and Emergency Response

The official overdose profile of Probetol is defined by the acute, life-threatening exaggeration of its effects on core physiological systems. Documented severe overdose presentations primarily involve profound bradycardia and hypotension, which can rapidly progress to cardiogenic shock and cardiac arrest. Central nervous system manifestations are common, including drowsiness, confusion, seizures, and coma. Bronchospasm and hypoglycemia are specific risks, with low blood sugar being common in children.

Urgent medical help must be sought immediately for any suspected overdose. Regulatory guidance mandates calling emergency services or the national Poison Help hotline for rapid assessment and transport. Treatment with Probetol must be stopped immediately to avoid further complications.

Specific symptomatic management measures are described in official labeling. For example, Glucagon is a key agent used for persistent hypotension and bradycardia in severe cases. Management also requires the administration of activated charcoal to limit drug absorption, and continuous ECG monitoring is required due to the risk of conduction disturbances like QRS widening. The use of Epinephrine (adrenaline) is generally not indicated as it may provoke uncontrolled hypertension.

Population-specific notes highlight that hypoglycemia (low blood sugar) is a particular and common risk in pediatric overdose cases, requiring careful observation.

Therapeutic Uses of Probetol

Quick Facts: Probetol Uses

  • Hypertension (High Blood Pressure)
  • Angina Pectoris (Chest Pain)
  • Arrhythmias (Irregular Heart Rhythms)
  • Migraine Prophylaxis
  • Essential Tremor Management

Probetol is a prescription medication used to assist in the management of several cardiovascular and non-cardiovascular conditions. It is indicated for the treatment of hypertension, or high blood pressure, and is also used to manage the symptoms of angina pectoris (chest pain).

This agent provides therapeutic assistance in controlling certain irregular heart rhythms (arrhythmias) and is also utilized for the long-term management of patients who have survived the acute phase of a myocardial infarction (heart attack). For non-cardiac domains, Probetol is indicated for the prophylaxis of migraine headaches, aiming to reduce the frequency of episodes. It further offers support in managing essential tremor and is an approved treatment option for certain types of infantile hemangioma.

Eligibility and Restrictions for Use

Eligibility for Probetol (Propranolol)

Probetol is approved for use in adults and for specific indications, pediatric populations, including infants aged five weeks to five months for a dedicated formulation. Eligibility is strictly defined by regulatory guidelines, focusing on cardiovascular, respiratory, and organ function status.


Regulatory Status Populations Prohibited or Restricted
Contraindicated Patients with bronchial asthma or a history of bronchospasm, cardiogenic shock, sinus bradycardia, and heart block greater than first degree. Use is also prohibited in patients with uncontrolled heart failure or a known hypersensitivity to Probetol.
Use with Caution Hepatic or renal impairment requires caution, as reduced organ function can alter the drug's clearance. Caution is also mandated for patients prone to hypoglycemia (low blood sugar), such as those undergoing prolonged fasting.
Age and Reproductive Status Infants younger than five weeks corrected age are contraindicated for the hemangioma indication. For pregnancy, Probetol is classified as Category C, permitted only if the potential benefit outweighs documented fetal risk. Use during lactation is generally not recommended due to drug excretion into breast milk.

These official statements define the mandatory boundaries for Probetol use, establishing absolute prohibitions for conditions affecting the heart and lungs, and requiring specialized consideration for populations with metabolic or organ function limitations.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Probetol

Interaction Scope

Property Description
Medicinal product categories with documented interactions Antiarrhythmics, Non-dihydropyridine Calcium Channel Blockers, Anti-depressants, Alpha Blockers, NSAIDs, Triptans, Anticoagulants.
Specific interacting medicines (if explicitly listed) Verapamil, Diltiazem, Clonidine, Rifampin, Fluoxetine, Quinidine, Lidocaine, Digoxin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic (PK) interaction via CYP enzyme metabolism (CYP2D6, CYP1A2, 2C19 inhibition/induction); Pharmacodynamic (PD) interaction (e.g., additive cardiovascular depression).
Timing-based interaction rules (if applicable) Probetol must be withdrawn several days before the abrupt cessation of Clonidine; co-administration with certain Multivitamins/Minerals requires a separation of at least two hours.
Population-specific interaction notes (if applicable) Caution is noted for use in patients with impaired hepatic or renal function due to potentially altered clearance; Probetol may prolong the hypoglycaemic response to insulin in diabetic patients.

Interaction Classifications (High-Level)

Classification Basis / Context
Interaction severity classification (as defined in official documents) Contraindicated Combination (e.g., Verapamil, Diltiazem); Clinically Significant Interaction (multiple CYP-mediated and PD-related interactions).
Interaction-context constraints (as defined in official documents) Interference with the effectiveness of Epinephrine used to treat serious anaphylaxis.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with inhibitors of CYP2D6, CYP1A2, and CYP2C19 increases the plasma concentration (exposure) of Probetol.
  • Inducers of hepatic metabolism, such as Rifampin and Cigarette Smoking, decrease the plasma concentration of Probetol, resulting in a documented loss of efficacy.
  • Food intake is documented to increase its oral bioavailability.
  • Co-administration with other cardiac depressants (e.g., Digoxin) or Alpha Blockers can lead to additive PD effects.

Connection to the overall interaction profile (2–4 sentences):

The regulatory interaction profile for Probetol is defined primarily by pharmacokinetic interactions resulting from its extensive hepatic metabolism via specific CYP enzymes, dictating which co-administered agents will raise or lower its exposure. Concurrently, the profile establishes formal restrictions and cautions based on pharmacodynamic reinforcement, requiring strict avoidance of combinations that can lead to severe cardiac depression. These official statements structure the product's regulatory constraints and administration requirements.

Mechanism of Action

Non-Selective Adrenergic Receptor Blockade

Probetol acts as a non-selective competitive antagonist of both the mathbfbeta1 and mathbfbeta2 adrenergic receptors. By occupying the binding sites for endogenous catecholamines like adrenaline, the drug initiates a cascade that lowers intracellular cyclic AMP (cAMP) levels, thereby suppressing the excitatory effects these hormones normally produce on the heart and vasculature.


️ Modulation of Cardiac and Renal Signaling

The mechanism directly impacts cardiac conduction and contractility, leading to a mathbf negative chronotropic (slowing heart rate) and mathbf negative inotropic (less forceful beat) effect. Simultaneously, beta1 blockade in the kidneys inhibits the release of renin, a key component of the mathbf Renin-Angiotensin-Aldosterone System (RAAS), which contributes to a reduction in peripheral vascular resistance and circulating volume.


Central Dampening of Sympathetic Tone

Probetol's lipophilic structure allows it to enter the central nervous system, where it facilitates the dampening of sympathetic outflow, complementing its peripheral actions. This central modulation influences the somatic manifestations of heightened adrenergic activity by modulating the downstream effects of increased central sympathetic signaling.

Dosage and Administration Information

Official Administration Guidelines

Probetol (Propranolol) administration is based on specific instructions concerning route, dosage, and timing. The primary method of use is the oral route, available in forms including immediate-release tablets, extended-release capsules, and an oral solution. The intravenous (IV) route is restricted to acute clinical scenarios requiring medical supervision.

Dosing and Scheduling

Treatment with immediate-release forms commonly begins with a starting dose of 40 mg twice daily for approved indications. The dosage is designed for gradual increase (titration) over defined intervals, such as weekly, until the necessary maintenance dose range is achieved, which may extend up to 240 mg daily. Extended-release capsules are designed for a simplified once-daily schedule, frequently administered at bedtime.

Administration Conditions

Instructions specify that immediate-release tablets and solution should be taken with food to ensure consistent drug absorption. Patients utilizing the extended-release capsule must not crush, chew, or open the formulation to preserve its sustained delivery mechanism. Special instructions apply to certain populations; for example, older adults generally begin treatment with the lowest available dose. When concluding therapy, all patients are instructed to perform a gradual dose reduction (tapering) over one to two weeks, as abrupt cessation is generally avoided in clinical practice.

Recent Clinical Evidence

Evidence for Use in Cardiovascular Conditions

The active ingredient in Probetol, Propranolol, was studied for use in conditions related to the heart and circulation, primarily Hypertension (high blood pressure), Angina Pectoris (chest pain), and certain irregular heart rhythms. Research relies on Randomized Controlled Trials (RCTs) and subsequent Meta-analyses, study designs used to evaluate patterns across patient groups.

For high blood pressure, studies reported measurements showing alterations in blood pressure, and this evidence is generally classified as High. For angina, research examined changes in the frequency of chest pain and exercise tolerance. This high level of evidence also applies to research monitoring heart rhythm and rate and its long-term research contexts for patients after a heart attack. Evidence concerning event reduction for uncomplicated hypertension is sometimes viewed as part of broader class research.

Evidence for Use in Neurogenic Conditions

Propranolol was also studied for uses affecting the nervous system, including the prevention of Migraine headaches and the management of Essential Tremor. Placebo-controlled trials for migraine prevention examined changes in monthly migraine days; findings support a Moderate level of evidence, though the full effect may require up to three months of observation. For essential tremor, RCTs evaluated tremor severity and functional activities, supporting a High level of evidence.

Evidence in Special Populations and Research Gaps

Specialized Phase 2/3 Trials were conducted in the infant population for proliferating Infantile Hemangioma, supporting a High level of evidence for this specific use. For older adults and those with comorbidities, data are often drawn from post-marketing observational settings, and subgroup findings are uncertain. Overall, research limitations include follow-up durations being limited for many non-cardiac indications, meaning there is limited information for long-term outcomes and durability of response.

Frequently Asked Questions (FAQ)

Common questions about Probetol (FAQ)

Q: Does Probetol cure the condition, or does it just help manage the symptoms?

Official information indicates that this medicine is designed to help control and manage certain conditions rather than providing a cure. Its purpose is generally described as helping to control and regulate symptoms during use.

Q: Does Probetol make you feel sleepy or tired during the day?

The official documentation for the active ingredient lists common adverse reactions that include fatigue, feeling tired, and a lack of energy. These effects, including fatigue and lack of energy, are commonly documented adverse reactions.

Q: Is it normal to feel a mild headache when first starting Probetol?

Headache is documented in official sources as a possible side effect of the medicine. This occurrence is noted in the product's official safety information.

Q: Can Probetol interact with common vitamins or supplements?

Official guidelines note that there can be interactions with certain supplements. Specifically, taking the medicine with multivitamins that contain minerals may potentially decrease its effectiveness. For this reason, regulatory documents state that a separation of at least two hours between the administration of these products is required.

Q: What happens if I stop taking Probetol suddenly?

Regulatory protocol requires a gradual dose reduction (tapering) when concluding therapy. Abrupt cessation is documented as potentially leading to serious complications, including an exacerbation of angina (chest pain) or a myocardial infarction (heart attack) for those with heart disease.

Q: Is there a generic version of Probetol available yet?

Official records from regulatory bodies, such as the FDA, confirm the approval of generic versions containing the active ingredient, Propranolol. This confirmation is based on available pharmaceutical documentation.

Q: How long has Probetol been available on the market?

The active ingredient in Probetol, Propranolol, has been available for an extended period. It received initial approval from the U.S. Food and Drug Administration (FDA) in November 1967.

Q: Are there any ongoing clinical trials for new uses of Probetol?

Yes, governmental databases, such as those maintained by the National Institutes of Health (NIH), indicate that there is ongoing research. These trials are examining new or specific applications of the active ingredient, Propranolol.

Q: Is Probetol considered a habit-forming or addictive medicine?

The medicine is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies. This classification is used for medicines that carry a high risk for dependence or abuse.

Q: What are the signs of a rare but serious allergic reaction to Probetol?

Official labels document signs associated with a rare, severe hypersensitivity reaction. These typically include rash, hives, swelling of the face, tongue, or throat, or difficulty breathing. Serious skin reactions are also documented.

Q: Does Probetol have any impact on mood or anxiety levels?

Yes, mood changes and feelings of depression are documented as adverse effects of the medicine in official product information. Additionally, disturbed sleep and nightmares are also listed among the possible side effects.

Q: Why is Probetol sometimes given as a shot instead of a pill?

The intravenous (IV) route for administration is restricted to acute clinical scenarios that require immediate medical supervision. This method is used when rapid action is necessary, such as for controlling fast heartbeats and abnormal heart rhythms.

Q: Can Probetol be taken if I am already taking an antidepressant?

The official interaction map documents interactions with certain categories of medicines, including antidepressants, due to effects on drug metabolism. More detailed information on this topic can be found in the Interactions with other medicines and products section.

Q: Does Probetol cause hair loss or skin reactions?

Hair loss is documented in the list of adverse effects for the active ingredient. Additionally, various types of skin reactions, including rare severe skin reactions, are noted in the product's safety information.

Q: What specific conditions must be met for a doctor to prescribe Probetol?

Eligibility is strictly defined by regulatory guidelines and is focused on a patient’s cardiovascular, respiratory, and organ function status. For example, use is prohibited, or 'contraindicated,' in patients with pre-existing conditions like bronchial asthma and certain types of heart block.

Q: What are the limits on how long Probetol can be used?

Official documents do not establish a universal limit on how long the medicine can be used. However, it is noted that research providing information on long-term outcomes and durability of response is limited for some of the non-cardiac uses.

Q: Can Probetol make birth control pills less effective?

The active ingredient in some oral contraceptives (ethinyl estradiol) may increase the plasma concentration of Probetol. This means the level of Probetol in the body could rise, which could potentially cause a greater decrease in heart rate and blood pressure.

Q: What is the risk of an interaction between Probetol and alcohol?

Official information indicates that combining the medicine with alcohol can lead to an additive depressor effect on blood pressure. The official information states that this combination can lead to additive depressor effects on blood pressure.

Q: Can I take pain relievers like Tylenol or Advil with Probetol?

The official interaction map lists the category of non-steroidal anti-inflammatory drugs (NSAIDs), which includes medicines like ibuprofen, as having documented interactions. Detailed information regarding this interaction category is available in the Interactions section.

Q: Is Probetol considered safe for older adults or the elderly?

Official administration guidelines state that older adults generally begin treatment with the lowest available dose, as this population may require specialized consideration.

Q: Can people with kidney or liver issues use Probetol?

Official guidelines mandate caution for use in patients with impaired hepatic (liver) or renal (kidney) function. The caution is mandated because reduced organ function has the potential to alter how the drug is cleared from the body.

Q: Does Probetol affect my ability to drive or operate machinery?

Official safety information indicates that the medicine may affect alertness or coordination. It is recommended to know how the medicine affects you before attempting activities that require high levels of concentration, such as driving or operating machinery.

Q: What happens if I accidentally take two doses close together?

The official product instructions specify that patients should not take a double dose to make up for a missed dose. This instruction is given because taking a double dose may increase the potential for experiencing unwanted side effects.

How should Probetol be stored and disposed of?

Storage and Handling Requirements

Propranolol Hydrochloride (Probetol) must be stored under specific environmental conditions to maintain its effectiveness, as defined by regulatory documents.

Requirement Official Condition (Regulatory)
Temperature Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection Must be protected from light, moisture, and excessive heat; Do not freeze capsules or oral solution.
Container Keep in a tight, light-resistant container and ensure the container remains tightly closed.

Stability and Disposal

The product must be kept out of the reach of children. The oral solution formulation has an in-use stability limit and must be discarded after 90 days from the first opening. Unused or expired medication must be disposed of in accordance with local requirements to avoid discharge into drains or water courses. If a drug take-back program is unavailable, follow the official guidelines for mixing the product with an undesirable substance (e.g., dirt) before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probetol found in:

A-Z Index: